title: Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison.
abstract: To compare daclatasvir + asunaprevir (DCV + ASV) versus sofosbuvir/ledipasvir (SOF/LDV) for hepatitis C virus genotype 1b in Japanese patients without NS5A polymorphisms at L31 and Y93H.
  
  
  
  All Phase III trials of SOF/LDV and DCV + ASV conducted in Japan were included. To adjust for cross-trial differences, DCV + ASV patients were weighted to match reported SOF/LDV summary baseline characteristics.
  
  
  
  After adjustment, the rate of SVR12 (99.3 vs 100%; p = 0.398) and discontinuation due to adverse events (1.3 vs 0.0%; p = 0.327) were similar between patients treated with DCV + ASV (n = 252) and SOF/LDV (n = 171).
  
  
  
  After adjusting for cross-trial differences in baseline characteristics, DCV + ASV and SOF/LDV were associated with similar efficacy and discontinuation due to adverse events in the treatment of hepatitis C virus genotype 1b in Japanese patients without NS5A polymorphisms.
authors.affiliation: Analysis Group Inc., 111 Huntington Avenue, 10th floor, Boston, MA 02199, USA.
authors.forename: Elyse
authors.initials: E
authors.lastname: Swallow
authors.affiliation: Analysis Group Inc., 111 Huntington Avenue, 10th floor, Boston, MA 02199, USA.
authors.forename: Caroline
authors.initials: C
authors.lastname: Kelley
authors.affiliation: Analysis Group Inc., 111 Huntington Avenue, 10th floor, Boston, MA 02199, USA.
authors.forename: James
authors.initials: J
authors.lastname: Signorovitch
authors.affiliation: Bristol-Myers Squibb, 100 Nassau Park Boulevard, Princeton, NJ 08540, USA.
authors.forename: Gail
authors.initials: G
authors.lastname: Wygant
authors.affiliation: Bristol-Myers Squibb, 100 Nassau Park Boulevard, Princeton, NJ 08540, USA.
authors.forename: Fiona
authors.initials: F
authors.lastname: McPhee
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use; D002219:Carbamates; D017326:Clinical Trials, Phase III as Topic; D004359:Drug Therapy, Combination; D005449:Fluorenes / Q000627:therapeutic use; D005838:Genotype; D016174:Hepacivirus; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007546:Isoquinolines / Q000627:therapeutic use; D011759:Pyrrolidines; D000069474:Sofosbuvir / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D014633:Valine / Q000031:analogs & derivatives
chemical_list: D000998:Antiviral Agents; D001562:Benzimidazoles; D002219:Carbamates; D005449:Fluorenes; D007093:Imidazoles; D007546:Isoquinolines; D011759:Pyrrolidines; D013449:Sulfonamides; C586541:ledipasvir; D014633:Valine; C549273:daclatasvir; C571889:asunaprevir; D000069474:Sofosbuvir
keywords: Japan; asunaprevir; daclatasvir; genotype 1; hepatitis C; ledipasvir; matching-adjusted indirect comparison; sofosbuvir